epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

Studies

Six studies at a glance

The fictional sponsors, compounds and sites are invented; the evidence behind every expectation is real. Data to September 30th 2026.

Open a study

Each study opens on its Overview, with tabs for its sites, KPIs, KRIs, QTLs, plan, design and risks. EPI-214 shows the most: a study well under way, behind its deadline, with a QTL outside its limit.

The portfolio

  • Patients randomised1,121across four studies
  • Sites open297in four running studies
  • Running studies with a red area2 of 4EPI-214, EPI-405
The portfolio: each study's progress and the status of each area it is watched for
Show countriesStudyRandomisedFinishEnrolmentSitesKRIsQTLs
EPI-301Non-small cell lung cancer, second lineRecruiting. Oncology171 of 400On time82% of plan5 of 10 behind19 of 159 flaggedAll 4 within
EPI-214Heart failure with reduced ejection fractionRecruiting. Cardiovascular472 of 82411 months late91% of plan60 of 113 behind33 of 120 flagged1 of 4 outside
EPI-118Treatment-resistant major depressive disorderStart-up. CNS and psychiatry0 of 243On timeToo earlyToo early0 of 135 flaggedToo early
EPI-405A rare inherited neuromuscular disorder (genetically confirmed)Recruiting. Rare disease7 of 6441 months late47% of planToo early0 of 18 flaggedToo early
EPI-512Moderate to severe ulcerative colitisRecruitment complete. Immunology and GI471 of 471Complete94% of plan40 of 70 behind31 of 70 flaggedAll 4 within
EPI-620Chronic obstructive pulmonary disease with frequent exacerbationsPlanning. Respiratory0 of 706In planningNo sites yetNo sites yetNo sites yetNo sites yet

Expand a row to see its countries without leaving the page; a status opens the tab behind it. Every colour comes from a threshold in the data with its basis, listed on the References page.